Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06420089 · ClinicalTrials.gov registry record · Phase 1

CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL)

A Phase 1 study of T Cell Non-Hodgkin Lymphoma, sponsored by Vittoria Biotherapeutics.

Recruiting
Registry status
Phase 1
Development phase
30
Enrollment target
2
Study locations

NCT06420089: Recruiting Phase 1 study of T Cell Non-Hodgkin Lymphoma, sponsored by Vittoria Biotherapeutics.

NCT06420089 is a Phase 1 study of T Cell Non-Hodgkin Lymphoma that is actively recruiting participants, run by Vittoria Biotherapeutics. The registered enrollment target is 30 participants, below the 44-participant average among 5 other T Cell Non-Hodgkin Lymphoma trials with a reported enrollment target (32% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06420089, a Phase 1 study of T Cell Non-Hodgkin Lymphoma, is actively recruiting participants, sponsored by Vittoria Biotherapeutics.

RECRUITING
Registry status
Phase 1
Development phase
30 participants
Enrollment target
2
Study locations

Study Summary

This is an open-label phase I study to determine the safety and recommended phase 2 dose (RP2D) of Senza5 CART5 cells in patients with relapsed or refractory CD5 positive nodal T cell NHL. RP2D will be based on the safety, tolerability, pharmacokinetics, and preliminary efficacy of Senza5 CART5 cells. This trial will evaluate up to 5 dose levels using the Bayesian Optimal Interval (BOIN) design enrolling 3 patients in each cohort to assess safety and achieve therapeutic levels so that the RP2D of Senza5 CART5 cells given as a single IV infusion can be determined.

Conditions Studied

T Cell Non-Hodgkin Lymphoma

Interventions

  • DRUG Senza5 CART5

Study Locations (2)

New York

  • Columbia University Irving Medical Center - New York

Pennsylvania

  • University of Pennsylvania - Abramson Caner Center - Philadelphia

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2024-10-04
Est. Completion 2029-08-30
Phase Phase 1

Sponsor

Vittoria Biotherapeutics

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06420089

The ClinicalTrials.gov registry entry for NCT06420089 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 44-participant average among 5 other T Cell Non-Hodgkin Lymphoma trials with a reported enrollment target (32% lower). The listed sponsor is Vittoria Biotherapeutics, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with T Cell Non-Hodgkin Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Senza5 CART5 is the first listed.

NCT06420089 reports 2 study locations spanning 2 distinct geographic areas - top geographies include New York, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT06420089 about?

NCT06420089 is a clinical study titled "CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL)". This is an open-label phase I study to determine the safety and recommended phase 2 dose (RP2D) of Senza5 CART5 cells in patients with relapsed or refractory CD5 positive nodal T cell NHL. RP2D will be based on the safety, tolerability, pharmacokinetics, and preliminary efficacy of Senza5 CART5 cell...

What is the current status of trial NCT06420089?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2024-10-04. Estimated completion is 2029-08-30.

What conditions does trial NCT06420089 study?

This clinical trial studies the following conditions: T Cell Non-Hodgkin Lymphoma.

What interventions are being tested in trial NCT06420089?

The interventions under investigation include: Senza5 CART5 (DRUG).

Who is sponsoring clinical trial NCT06420089?

This trial is sponsored by Vittoria Biotherapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06420089 being conducted?

This trial has 2 study locations across New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for T Cell Non-Hodgkin Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

T Cell Non-Hodgkin Lymphoma

All registered trials for this condition

New York

All trials with a study site in New York

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Related

Compare this shortlist side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.